ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

FDA Weighs Action On Genzyme Plant

by Lisa M. Jarvis
March 29, 2010 | APPEARED IN VOLUME 88, ISSUE 13

Following repeated problems at Genzyme’s Allston, Mass., site, FDA appears ready to take legal action to force the biotech firm to comply with current Good Manufacturing Practices. Genzyme said FDA is likely to propose a consent decree, which calls for a third party to inspect operations over time and is usually accompanied by a hefty fine. Manufacturing deficiencies at Allston have already cost Genzyme hundreds of millions of dollars in sales of the Gaucher disease treatment Cerezyme and the Fabry disease drug Fabrazyme. Meanwhile, patients with the rare diseases have had to restrict doses of the drugs because of the manufacturing woes.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment